Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02909686
Other study ID # F150318011
Secondary ID CDMRP-GW130015
Status Completed
Phase N/A
First received
Last updated
Start date July 2016
Est. completion date September 2022

Study information

Verified date March 2024
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall objective of this protocol is to test if Gulf War Illness (GWI) involves chronic inflammation that cannot be measured with typical techniques. The investigators will be observing the effects of nine different botanical compounds (supplements) that are known to suppress inflammation. If one of those supplements helps the symptoms of GWI, it will give the investigators information about what is wrong in people with GWI.


Description:

There is still a poor understanding of the pain, fatigue, and other symptoms that affect approximately 250,000 veterans. The precise mechanism of Gulf War Illness (GWI) is not understood, and there is no targeted treatment for the condition. A current model for GWI points to the central nervous system, immune cells, called microglia that may be hyperactive in patients with GWI. Discovering effective treatments for this disorder is a top priority of GWI research. Given the investigator's preliminary data, it is suspected that GWI is a form of low-level neuroinflammation that involves hypersensitivity of receptors on microglia. In order to help test that hypothesis, the investigators will be administering supplements that have been shown in vitro or animal in vivo to suppress microglia function in a way that is anti-inflammatory and neuroprotective. If any of these agents suppress symptoms in GWI, it will give the investigators important information about the disease that may allow for creation of better diagnostic tools and treatments in future research studies. Observing the effects of the selected nine anti-inflammatory botanical compounds, in this clinical study, is a strong compliment to the ongoing mechanistic GWI research.


Recruitment information / eligibility

Status Completed
Enrollment 39
Est. completion date September 2022
Est. primary completion date September 2019
Accepts healthy volunteers No
Gender Male
Age group 39 Years to 65 Years
Eligibility Inclusion Criteria: 1. Male 2. Age 39-65, inclusive 3. Veterans who meet the Kansas inclusion criteria for GWI 4. Present in Persian Gulf between 1990 and August 1991 5. Patient completes daily report during 2 week baseline period (at least 80% completion rate) 6. Able to receive a venous blood draw Exclusion Criteria: 1. Positive rheumatoid factor at screening 2. Positive anti-nuclear antibody at screening 3. C-reactive protein> 3mg/L at screening 4. Erythrocyte Sedimentation Rate> 40mm/hr at screening 5. Auto-immune disorder 6. Diagnosed Rheumatologic Condition 7. Major PTSD symptoms 8. Hypotension (under 90/60 mm Hg) or history of cardiovascular disease 9. Antihypertensive, anticoagulant medication, nitroglycerine, lithium medication use 10. Diabetes with Hemoglobin A1C >9% 11. History of anaphylaxis to study botanical compounds 12. Current daily use of opioid medication 13. Hospital Anxiety and Depression Scale, Depression subscale score of 16 or higher at baseline 14. Current litigation of worker's compensation claim 15. Blood or clotting disorder 16. Acute infection (body temperature over 100 degrees F) 17. Current daily use of confounding-anti-inflammatory medication as part of regular medication regimen 18. Individuals that are not able to read & understand English

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Boswellia Serrata

Curcumin

Epimedium

Fisetin

Luteolin

Nettle

Pycnogenol

Reishi Mushroom

Resveratrol

Placebo


Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama

Sponsors (2)

Lead Sponsor Collaborator
University of Alabama at Birmingham Congressionally Directed Medical Research Programs

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in overall Gulf War Illness disease severity Self reported Gulf War Illness symptom severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=no symptoms; 100=severe symptoms). Average disease severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline.
Secondary Change from baseline in Pain Severity Self reported pain severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=no pain; 100=severe pain). Average pain severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline.
Secondary Change from baseline in Fatigue Severity Self reported fatigue severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=not fatigued at all; 100=severely fatigued). Average fatigue severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline.
Secondary Change from baseline in Cognitive Symptom Severity Self reported cognitive symptom severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=not [able to think and remember] clearly at all; 100=[able to think and remember] very clearly). Average cognitive symptom severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline.
Secondary Change from baseline in Mood Symptom Severity Self reported mood symptom severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=not good [mood] at all; 100=extremely good [mood]). Average mood severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline.
Secondary Change from baseline in Dermatological Symptom Severity Self reported dermatological symptom severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=no skin problems at all; 100=severe skin problems). Average dermatological symptom severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline.
Secondary Change from baseline in Respiratory Symptom Severity Self reported respiratory symptom severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=no breathing or respiratory problems at all; 100=severe breathing or respiratory problems). Average respiratory symptom severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline.
Secondary Change from baseline in Gastrointestinal Symptom Severity Self reported gastrointestinal symptom severity reported twice daily, in the morning and evening, for the duration of the study. Single item scored 0-100 (0=no bowel or GI problems at all; 100=severe bowel or GI problems). Average gastrointestinal symptom severity during the last two weeks of each treatment, compared to average severity during the last two weeks of placebo, as well as baseline.
See also
  Status Clinical Trial Phase
Recruiting NCT04254627 - TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset Phase 1
Terminated NCT02011542 - Probiotic (VSL #3) for Gulf War Illness Phase 2/Phase 3
Recruiting NCT03078530 - Probiotic (Visbiome) for Gulf War Illness Phase 2/Phase 3
Recruiting NCT04058275 - "Immunomodulation in GWI (Phlebotomy)"
Recruiting NCT04255498 - Understanding GWI: Integrative Modeling Phase 1
Completed NCT02782780 - Cognitive Behavioral Therapy for Insomnia for Gulf War Illness N/A
Recruiting NCT02983734 - D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS) Phase 2
Recruiting NCT05972291 - Mechanisms of Gulf War Illness N/A
Recruiting NCT04182659 - Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms N/A
Recruiting NCT04046536 - rTMS in Alleviating Pain and Co-Morbid Symptoms in Gulf War Veterans Illness (GWVI) N/A
Recruiting NCT05377242 - Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI N/A
Recruiting NCT05675878 - Confirmation of Diet as a Treatment for Gulf War Illness Phase 3
Recruiting NCT05736146 - Validating Gulf War Illness Blood Biomarkers
Not yet recruiting NCT05820893 - Resistant Potato Starch to Alleviate GWI Phase 2
Terminated NCT01846182 - Research Examining Gulf War Illness in Our Nations Service Members Phase 2
Active, not recruiting NCT05252949 - OEA for Targeting Lipid Metabolism in GWI N/A
Completed NCT02378025 - Treating Chronic Pain in Gulf War Illness N/A
Completed NCT02865460 - Coenzyme Q10 Phase III Trial in Gulf War Illness Phase 3
Completed NCT01291758 - Exercise in Gulf War Illness (GWI)
Completed NCT01011348 - Q10 for Gulf War Veterans N/A